Drugs / Trifluridine/Tipiracil
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05062889 | May 2023 → Oct 2027 | malignant colon neoplasm | Gruppo Oncologico del Nord-Ovest | Suspended | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Trifluridine/Tipiracil | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05062889 ↗ |
| Route | Oral | “35 mg/m2/bid per os days 1-5 and 8-12” NCT05062889 ↗ |